Your browser doesn't support javascript.
Advances and Challenges of CAR T Cells in Clinical Trials.
Recent Results Cancer Res ; 214: 93-128, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-31473850
As a specifically programmable, living immunotherapeutic drug, chimeric antigen receptor (CAR)-modified T cells are providing an alternative treatment option for a broad variety of diseases including so far refractory cancer. By recognizing a tumor-associated antigen, the CAR triggers an anti-tumor response of engineered patient's T cells achieving lasting remissions in the treatment of leukemia and lymphoma. During the last years, significant progress was made in optimizing the CAR design, in manufacturing CAR-engineered T cells, and in the clinical management of patients showing promise to establish adoptive CAR T cell therapy as an effective treatment option in the forefront.





Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Receptores de Antígenos Quiméricos / Neoplasias Aspecto clínico: Terapia Limite: Humanos Idioma: Inglês Revista: Recent Results Cancer Res Ano de publicação: 2020 Tipo de documento: Artigo País de afiliação: Alemanha